|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003420,
umls-concept:C0009491,
umls-concept:C0013227,
umls-concept:C0023660,
umls-concept:C0030705,
umls-concept:C0205307,
umls-concept:C0332293,
umls-concept:C0681850,
umls-concept:C0743223,
umls-concept:C1550501,
umls-concept:C1579762,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1981-2-26
|
|
pubmed:abstractText |
1 The disposition kinetics of lignocaine and antipyrine were compared in eight normal subjects and in eleven patients receiving chronic therapy with antiepileptic drugs. The urinary excretion of D-glucaric acid (D-GA) was measured in 16 subjects. 2 In patients treated with antiepileptic drugs antipyrine clearance and D-GA excretion were significantly increased, whereas lignocaine biovailability was significantly reduced. 3 When all the subjects included in the study were considered, a significant positive correlation could be found between the apparent oral clearance of lignocaine (Dose/area under the blood concentration curve) and both antipyrine clearance (r = 0.73) and D-GA excretion (r = 0.74). 4 When normal subjects and epileptic patients were considered separately, a significant positive correlation could be confirmed between the apparent oral clearance of lignocaine and both antipyrine clearance (r = 0.71) and D-GA excretion (r = 0.76) in normal subjects, and between antipyrine clearance and D-GA excretion (r = 0.75) in epileptic patients. 5 These results suggest that the reduction of the oral availability of lignocaine in epileptic patients is secondary to induction of first-pass metabolism of the latter drug.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-111889,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-1164816,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-1164821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-13715411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-16748985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-239673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-332216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4105797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4149412,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4177776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4210516,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4418356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4423599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-444364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4611464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4683073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4688187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-4723263,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-487696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5010683,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5019220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5071697,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5099888,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5428253,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-552293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5540706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-5569980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-668797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-760753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-837635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-839445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-849678,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-894100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-913025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7437261-982059
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
491-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7437261-Adolescent,
pubmed-meshheading:7437261-Adult,
pubmed-meshheading:7437261-Anticonvulsants,
pubmed-meshheading:7437261-Antipyrine,
pubmed-meshheading:7437261-Biological Availability,
pubmed-meshheading:7437261-Enzyme Induction,
pubmed-meshheading:7437261-Glucaric Acid,
pubmed-meshheading:7437261-Humans,
pubmed-meshheading:7437261-Kinetics,
pubmed-meshheading:7437261-Lidocaine,
pubmed-meshheading:7437261-Middle Aged
|
|
pubmed:year |
1980
|
|
pubmed:articleTitle |
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
